Delcath Systems (DCTH) Reports Q2 Loss of $0.30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- AppLovin gains market share among e-commerce advertisers
- Wall Street ends higher as investors turn to earnings season
Delcath Reports 2015 Second Quarter Financial Results
August 5, 2015 8:00 AM EDTNEW YORK, Aug. 5, 2015 /PRNewswire/ --Â Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2015.Â
Highlights of the second quarter and recent weeks included:
Quarterly product revenue of $0.5 million, an increase of nearly 85.7% compared with the second quarter of 2014 Total operating expenses decreased by 35.1% to $4.0 million from $6.1 million in the second quarter of 2014 Enrollment opened for an... MoreDelcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress
August 4, 2015 8:00 AM EDTNEW YORK, Aug. 4, 2015 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that two abstracts summarizing data from studies in Europe and the U.K. of treatment with the Delcath Hepatic CHEMOSAT® Delivery System (CHEMOSAT) will be presented at the upcoming European Association of Dermato Oncology (EADO) annual congress, which will be held in Marseille, France, October 28-31, 2015.
The abstracts are:
Treating Unresectable Liver... More